Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
Overall, the trials showed that a once-monthly intravenous dose of anifrolumab was able to reduce disease activity across organ system in SLE, including skin and joints, and also helped patients ...
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn ... Lupus is an autoimmune disease in which the immune system attacks healthy tissue in the body instead ...
Hosted on MSN8mon
A lupus breakthrough, bubonic plague case and pig kidney transplant update: What to know about this week's health storiesWhat it means: Right now, the common management of lupus involves suppressing the immune system ... participants anifrolumab, a drug that blocks interferon, prevented the T cell imbalance that ...
Hosted on MSN1mon
Anifrolumab Tied to Less Organ Damage for Patients With LupusTHURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback